Rocket Lab Insider Selling Hits 130-Zero Count as Record Fundamentals and Index Entry Push Back
19.06.2026 - 19:25:20 | boerse-global.de
The insider trading ledger at Rocket Lab tells a lopsided story. Over the past six months, company insiders have executed 130 transactions — every single one a sale. Not a single open-market purchase has been recorded. General Counsel Arjun Kampani alone unloaded 88,000 shares on June 18 at an average price of $107.98, pocketing roughly $9.5 million. He still holds 264,705 shares worth about $28.6 million. Chief Financial Officer Adam Spice has been the most active seller, shedding 1.49 million shares across 18 transactions for an estimated $116 million. Chief Executive Peter Beck sold approximately 18,900 shares in five trades, netting around $1.3 million.
A closer look reveals nuance. The bulk of these sales occurred through Rule 10b5-1 trading plans tied to automatic tax withholdings on vesting restricted stock units. Spice, Chief Operating Officer Frank Klein, and Kampani himself all followed that pattern in May. Such pre-arranged programs say little about an executive's personal market view. Yet the sheer volume — 130 outs, zero ins — creates a narrative that investors cannot ignore, especially with the stock down roughly 31% from its late-May all-time high.
SpaceX Gravity and a Lost Day
That drawdown has a specific trigger. On June 12, SpaceX made its public market debut, and Rocket Lab shares plunged nearly 11% in a single session. The logic was straightforward: a new, dominant player in commercial spaceflight sucked capital away from smaller rivals. Over the following days, Rocket Lab failed to recoup those losses, leaving the stock 20% lower on a 30-day basis. Even SpaceX itself cooled after its initial pop — the Elon Musk-led giant dropped more than 6% on Thursday to $178.50 after briefly ranking among the five most valuable companies globally. IPOX Schuster analysts attributed the pullback to profit-taking of a magnitude that was always likely after such a large IPO.
The selloff in Rocket Lab caught the attention of KeyBanc analyst Michael Leshock. On June 15 he upgraded the stock to Buy/Overweight and lifted his price target to $135, arguing the market had overreacted. The post-SpaceX dip, he wrote, offered a favorable entry point. Rocket Lab traded at €92.10 per primary reporting and €92.30 per secondary coverage — just above its 50-day moving average of €90.94 but far from the year's high of €133.80.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Record Operations Beneath the Noise
If the insider sales and SpaceX shadow suggest weakness, the operating numbers tell a different story. First-quarter revenue climbed either 63.4% or 63.5% (depending on the source) year-over-year to $200.3 million. Gross margin under GAAP reached 38.2%. The backlog doubled to a record $2.2 billion — a 108% surge. The launch manifest now exceeds 70 contracted missions. In the first quarter alone, Rocket Lab signed 31 new Electron and HASTE launch agreements along with five Neutron contracts, surpassing the total for all of 2025.
The defense business provides a stabilizing floor. Two Space Development Agency contracts combine for more than $1.3 billion, and a hypersonic test program adds $190 million. The Space Systems segment now accounts for nearly two-thirds of total revenue. Management guided second-quarter revenue to a range of $225 million to $240 million, with quarterly results expected in August.
Neutron: The Make-or-Break Variable
The core of the investment thesis rests on the Neutron rocket, Rocket Lab's medium-lift vehicle designed to lift the company into a new competitive tier. Analysts estimate that 20 annual Neutron launches could generate more than $1 billion in revenue — exceeding the entire company's top line for 2025. Yet Neutron has never flown. A fuel-tank test failure pushed the first launch into the fourth quarter of 2026, a timeline the company maintains. Production capacity is being scaled to four rockets per year. Rocket Lab management argues that SpaceX is increasingly focused on Starlink and Starship, leaving room for Neutron to carve out a niche in the launch market.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Structural Demand Arrives Sunday
One counterweight to the insider-selling pressure arrives this weekend. As part of its quarterly rebalancing, the Nasdaq-100 will add Rocket Lab on Monday, June 22. The inclusion triggers automatic purchases from index funds and ETFs, creating a structural demand wave that could temporarily absorb supply. Passive buyers such as Vanguard, which already holds 47.4 million shares, and Baillie Gifford, with 17.9 million shares, will be forced to increase their positions. Institutions already own 71.78% of the float.
Valuation remains the elephant in the room. Even after the pullback, the stock trades 43% above its 200-day moving average and has surged roughly 266% over the past 12 months. The annualized 30-day volatility stands above 92%. Little margin for error exists. This week's index inclusion will test whether passive demand can shift sentiment — or whether the valuation debate and insider exodus will keep the stock pinned down.
Ad
Rocket Lab Stock: New Analysis - 19 June
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
